Active Recombinant Human WT1, Flag-tagged

• Cat.No.: WT1-1199H
• Product Overview: The N-terminal Flag-tagged WT-1 protein (residue 1-446, including exon 5 but without KTS) was expressed in a baculovirus system and purified by affinity and FPLC chromatography.

Specification

• Description: This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilm''s tumors. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described. In several variants, there is evidence for the use of a non-AUG (CUG) translation initiation site upstream of and in-frame with the first AUG. Authors of PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated.
• Source: Baculovirus-insect cell
• Species: Human
• Tag: Flag
• Bio-activity: 1 unit equals 1 nanogram of protein. 2-10 units are sufficient for a gel mobility shift assay in a 20µl reaction. 50-200 units are required for a reconstituted transcription assay and 100 units are sufficient for a protein-protein interaction assay.
• Molecular Mass: 55.7 kDa.
• Purity: Purified protein is greater than 95% homogeneous based on SDS-PAGE analysis.
• Applications: Recombinant WT-1 protein can be used for: 1) in vitro function studies including transcription, DNA or RNA binding assays; 2) protein-protein interaction assay; and 3) cell growth and proliferation assays.
• Storage Buffer: 20 mM Tris-Cl (pH 8.0), 20% Glycerol, 100 mM KCl, 1 mM DTT and 0.2 mM EDTA
• Protein length: 1-446
• Publication:
  WT1 Recruits TET2 to Regulate Its Target Gene Expression and Suppress Leukemia Cell Proliferation. (2015)
  WT1 interacts with MAD2 and regulates mitotic checkpoint function. (2014)

Gene Information

• Gene Name: WT1 Wilms tumor 1 [ Homo sapiens (human) ]
• Official Symbol: WT1
• Synonyms: WT1; GUD; AWT1; WAGR; WT33; NPHS4; WIT-2; EWS-WT1; Wilms tumor 1; Wilms tumor protein; amino-terminal domain of EWS|last three zinc fingers of the DNA-binding domain of WT1
• Gene ID: 7490
• mRNA Refseq: NM_000378
• Protein Refseq: NP_000369
• MIM: 607102
• UniProt ID: P19544
• Chromosome Location: 11p13
• Pathway: Integrated Pancreatic Cancer Pathway; Regulation of Telomerase; Transcriptional misregulation in cancer
• Function: C2H2 zinc finger domain binding; RNA binding; RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription

Reviews

10/10/2020

It has been widely employed in protein electron microscopy structure analysis, where it has demonstrated remarkable efficacy.

10/25/2019

Broad applicability make it a valuable asset for a wide range of research endeavors.

05/07/2017

Researchers can rely on the WT1 Protein to deliver reliable and reproducible results, facilitating robust data interpretation and scientific advancements.

Q&As

What therapeutic strategies are being explored for cancers with abnormal WT1 expression?

Targeted therapies and immunotherapies aimed at inhibiting or modulating WT1 expression are being investigated for their potential in cancer treatment.

In what other cancers is the WT1 protein targeted for diagnostic purposes?

Apart from Wilms' tumor, WT1 is examined in leukemia, mesothelioma, and some solid tumors as a diagnostic marker.

Can WT1 be a target for personalized cancer therapy?

Yes, understanding the WT1 status in a patient's cancer can guide the development of personalized treatment plans, potentially improving outcomes.

Are there any ongoing clinical trials focused on the WT1 protein and cancer?

Yes, there are several clinical trials exploring the role of WT1 as a therapeutic target and its potential in cancer treatment.

How does the WT1 protein contribute to the prognosis of cancer patients?

High levels of WT1 expression are often associated with poor prognosis in various cancers, indicating a more aggressive disease course.